Patients with low PSMA expression, particularly those with PSMA-negative but FDG-avid disease, may derive greater benefit from chemotherapy: trials combining [177Lu]Lu-PSMA-617 followed by pembrolizumab, using 68Ga-PET/CT and/or [18F]FDG PET, have demonstrated anti-tumour activity even in low or PSMA-negative disease [28, 29]. The gene discussed is FOLH1; the disease is neoplasm.